Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway

Clinical and Experimental Hypertension

Volumn 39, Issue 1, 2017, Pages 34-41

  Gao, Hua ^a   Cheng, Yuqing ^a   Zong, Liguo ^b   Huang, Linian ^a   Qiao, Chenchen ^c   Li, Wei ^a   Gong, Beilei ^a   Hu, Junfeng ^a   Liu, Haitao ^a   Wang, Xiaojing ^a   Zhao, Chengling ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b Department of Internal Medicine Zaozhuang Municipal Hospital   (China)

^c Bengbu First Peoples Hospital   (China)

Author keywords

Aspirin; ERK1 2; nonsteroidal anti inflammatory drugs; pulmonary arterial hypertension

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLSALICYLIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCROTALINE; SODIUM CHLORIDE; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; FLAVONOID; NOS3 PROTEIN, HUMAN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; LUNG CAPILLARY; MALE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; NONHUMAN; PULMONARY ARTERY; RAT; RIGHT VENTRICULAR SYSTOLIC PRESSURE; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; VASCULAR REMODELING; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; PATHOLOGY; SPRAGUE DAWLEY RAT; SYSTOLE;

ANIMALS; ASPIRIN; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; FLAVONOIDS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MAP KINASE SIGNALING SYSTEM; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SYSTOLE; VASCULAR REMODELING;

EID: 85008350910     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641963.2016.1210620     Document Type: Article

References (33)

1. McLaughlin VV, McGoon MD., Pulmonary arterial hypertension. Circulation 2006;114:1417–31.
2. Latus H, Delhaas T, Schranz D, Apitz C., Treatment of pulmonary arterial hypertension in children. Nat Rev Cardiol 2015; 12(4):244–54.
3. Zhang Y, Wang Y, Yang K, et al. BMP4 increases the expression of TRPC and basal [Ca2+]i via the p38MAPK and ERK1/2 pathways independent of BMPRII in PASMCs. PLoS One 2014;9:e112695.
4. Veit F, Pak O, Egemnazarov B, et al. Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. Antioxid Redox Signal 2013;19:2213–31.
5. Zhang B, Shen M, Xu M, et al. Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension. Mediators Inflamm 2012;2012:840737.
6. Thun MJ, Henley SJ, Patrono C., Nonsteroidal anti-inflammatory drugs as anticancer agents:mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252–66.
7. Shiff SJ, Rigas B., The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999;190:445–50.
8. Rakotoniaina Z, Guerard P, Lirussi F, et al. Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. Naunyn Schmiedebergs Arch Pharmacol 2008;378:241–51.
9. [Shen L, Shen J, Pu J, He B., Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. Cell Biochem Biophys 2011;61:23–31.
10. Chen L, He Y, Huang H, et al. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines:in vitro toxicity and mechanism study. Med Oncol 2008;25:161–71.
11. Zhang H, Li Z, Wang K., Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo. Oncol Rep 2014;31:1954–60.
12. Wang L, Wu J, Zhang W, et al. Effects of aspirin on the ERK and PI3K/Akt signaling pathways in rats with acute pulmonary embolism. Mol Med Rep 2013;8:1465–71.
13. Balestra GM, Mik EG, Eerbeek O, et al. Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension:mitochondrial inhibition as driver of cardiac failure? Respir Res 2015;16:6.
14. Sirmagul B, Ilgin S, Atli O, et al. Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension. Clin Exp Hypertens 2013;35:220–7.
15. Tang B, Chen GX, Liang MY, et al. Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats. Int J Cardiol 2015;180:134–41.
16. Sharma S, Umar S, Potus F, et al. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 2014;130:776–85.
17. Li W, Guo A, Wang L, et al. Expression of peptide fragments from proADM and involvement of MAPK signaling pathways in pulmonary remodeling induced by high pulmonary blood flow. Congenit Anom (Kyoto) 2016;56(1):28–34.
18. Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008;118:1846–57.
19. Fernandez RA, Wan J, Song S, et al. Upregulated STIM2, TRPC6 and Orai2 Contribute to the Transition of Pulmonary Arterial Smooth Muscle Cells from a Contractile to Proliferative Phenotype. Am J Physiol Cell Physiol 2015;308(8):C581–93.
20. Li QY, Zhu YF, Zhang M, et al. Chlorogenic acid inhibits hypoxia-induced pulmonary artery smooth muscle cells proliferation via c-Src and Shc/Grb2/ERK2 signaling pathway. Eur J Pharmacol 2015;751:81–8.
21. Guo H, Zhang X, Cui Y, et al. Isorhynchophylline protects against pulmonary arterial hypertension and suppresses PASMCs proliferation. Biochem Biophys Res Commun 2014;450:729–34.
22. Biasin V, Chwalek K, Wilhelm J, et al. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. Int J Biochem Cell Biol 2014;54:137–48.
23. Asada H, Paszkowiak J, Teso D, et al. Sustained orbital shear stress stimulates smooth muscle cell proliferation via the extracellular signal-regulated protein kinase 1/2 pathway. J Vasc Surg 2005;42:772–80.
24. Robbins IM, Kawut SM, Yung D, et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 2006;27:578–84.
25. Cho M, Kabir SM, Dong Y, et al. Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells. J Cancer 2013;4:671–8.
26. Im SR, Jang YJ., Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells. Biochem Biophys Res Commun 2012;424:65–70.
27. Budhiraja R, Tuder RM, Hassoun PM., Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159–65.
28. Matsuo S, Saiki Y, Adachi O, et al. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension. J Thorac Cardiovasc Surg 2015;149(3):902–9.
29. Kuriyama S, Morio Y, Toba M, et al. Genistein attenuates hypoxic pulmonary hypertension via enhanced nitric oxide signaling and the erythropoietin system. Am J Physiol Lung Cell Mol Physiol 2014;306:L996–1005.
30. Xiao Z, Wang T, Qin H, et al. Endoplasmic reticulum Ca2+ release modulates endothelial nitric-oxide synthase via extracellular signal-regulated kinase (ERK) 1/2-mediated serine 635 phosphorylation. J Biol Chem 2011;286:20100–8.
31. Chung HH, Dai ZK, Wu BN, et al. KMUP-1 inhibits pulmonary artery proliferation by targeting serotonin receptors/transporter and NO synthase, inactivating RhoA and suppressing AKT/ERK phosphorylation. Vascul Pharmacol 2010;53:239–49.
32. Lin YW, Huang CY, Chen YH, et al. GroEL1, a heat shock protein 60 of Chlamydia pneumoniae, impairs neovascularization by decreasing endothelial progenitor cell function. PLoS One 2013;8:e84731.
33. Chen C, Chai H, Wang X, et al. Chlamydia heat shock protein 60 decreases expression of endothelial nitric oxide synthase in human and porcine coronary artery endothelial cells. Cardiovasc Res 2009;83:768–77.